Mersana Therapeutics, Inc. (MRSN) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-01-06

Mersana Therapeutics, Inc. (MRSN) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every MRSN SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Mersana Therapeutics, Inc. (MRSN)

SEC CIK	0001442836

Recent MRSN Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-01-06	Hack Andrew A. F.	Insider	J — Other acquisition / disposition	578	—	—	SEC
2026-01-06	Hack Andrew A. F.	Insider	J — Other acquisition / disposition	346.5K	—	—	SEC
2025-09-12	Huber Martin H. Jr.	President, CEO	S — Open-market sale	2.0K	$7.31	$15K	SEC
2025-09-11	Huber Martin H. Jr.	President, CEO	M — Option exercise	6.7K	$0.00	—	SEC
2024-12-19	EcoR1 Capital, LLC	10% Owner	J — Other acquisition / disposition	8.04M	—	—	SEC
2024-10-28	Bala Mohan	SVP, Chief Development Officer	S — Open-market sale [10b5-1]	1.9K	$1.90	$4K	SEC
2024-10-25	Bala Mohan	SVP, Chief Development Officer	M — Option exercise [10b5-1]	6.2K	$0.00	—	SEC
2024-10-03	Mandelia Ashish	VP, Chief Accounting Officer	S — Open-market sale [10b5-1]	3.4K	$1.96	$7K	SEC
2024-10-03	Bala Mohan	SVP, Chief Development Officer	S — Open-market sale [10b5-1]	5.6K	$1.96	$11K	SEC
2024-10-03	DeSchuytner Brian	SVP, COO & CFO	S — Open-market sale [10b5-1]	5.6K	$1.96	$11K	SEC
2024-10-03	Carvajal Alejandra	SVP, Chief Legal Officer	S — Open-market sale [10b5-1]	5.6K	$1.96	$11K	SEC
2024-10-03	Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	S — Open-market sale [10b5-1]	5.6K	$1.96	$11K	SEC
2024-10-02	Bala Mohan	SVP, Chief Development Officer	S — Open-market sale [10b5-1]	8.1K	$2.00	$16K	SEC
2024-10-02	Lowinger Timothy B	SVP, Chief Sci.&Tech. Officer	S — Open-market sale [10b5-1]	8.1K	$2.00	$16K	SEC
2024-10-02	DeSchuytner Brian	SVP, COO & CFO	S — Open-market sale [10b5-1]	8.1K	$2.00	$16K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Mersana Therapeutics, Inc. (MRSN). Updated in real time as new filings are submitted to the SEC.

Recent Insider Filings

2026-01-06 — Hack Andrew A. F. (Insider)
2025-10-28 — Bala Mohan (SVP, Chief Development Officer)
2025-09-11 — Huber Martin H. Jr. (President, CEO)
2025-06-12 — Hege Kristen (Director)
2025-06-12 — MOTT DAVID M (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in MRSN insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

MRSN Insider Trading — FAQ

What is the latest insider trade for MRSN?: Mersana Therapeutics, Inc. (MRSN) had 0 insider filings in the last 90 days, with the most recent on 2026-01-06. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying MRSN stock?: 0 insider purchases of MRSN were filed in the last 90 days.
How many insiders are selling MRSN stock?: 0 insider sales of MRSN were filed in the last 90 days.
Where can I see MRSN SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every MRSN SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live MRSN dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.